| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/25/2002 | DE19983487C1 Verfahren zur Herstellung von Citalopram A process for the preparation of citalopram |
| 07/25/2002 | DE10104327A1 New 11beta-halo-testosterone derivatives useful in male hormone replacement therapy and in male fertility control |
| 07/25/2002 | DE10102944A1 Production of 3-cyano-1H-indol-7-yl)-(4-(4-fluorophenethyl)piperazin-1-yl)-methanone useful as a selective 5-HT2A antagonist comprises use of an indolecarboxylic acid ester as the starting material |
| 07/25/2002 | DE10102629A1 Antitumor agents having antimitotic and tubulin polymerization inhibiting action, comprising new or known 2-acyl-indole derivatives or aza analogs |
| 07/25/2002 | DE10102337A1 Preparing ester containing polyunsaturated fatty acids, useful e.g. in animal or human nutrition, by transforming organism with desaturase gene from Phaeodactylum tricornatum |
| 07/25/2002 | DE10102322A1 New disubstituted and trisubstituted benzene derivatives useful as coagulation inhibitors for the treatment of thromboembolic diseases |
| 07/25/2002 | DE10101522A1 Composition for treating collagenase-linked degenerative diseases, e.g. atherosclerosis, cancer and infections, comprises ascorbate and a fibrinolysis inhibitor |
| 07/25/2002 | CA2443895A1 Differential delivery of nitric oxide |
| 07/25/2002 | CA2443080A1 Lipid-based nitric oxide donors |
| 07/25/2002 | CA2441350A1 Methods to treat autoimmune and inflammatory conditions |
| 07/25/2002 | CA2437038A1 Method of determining a chemotherapeutic regimen based on ercc1 and ts expression |
| 07/25/2002 | CA2436122A1 A process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds |
| 07/25/2002 | CA2435692A1 Pyrrole derivates for treating cytokine mediated diseases |
| 07/25/2002 | CA2435374A1 Presbyopia treatment by reducing and preventing lenticular disulfide crosslinks |
| 07/25/2002 | CA2435322A1 Anticancer treatment using triptolide prodrugs |
| 07/25/2002 | CA2435305A1 Extended release pharmaceutical compositions containing beta-lactam antibiotics |
| 07/25/2002 | CA2435180A1 A virus causing respiratory tract illness in susceptible mammals |
| 07/25/2002 | CA2435117A1 Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases |
| 07/25/2002 | CA2435081A1 Method for producing polyunsaturated fatty acids, novel biosynthesis genes and novel plant expression constructs |
| 07/25/2002 | CA2435077A1 Preparation for improved dietary utilisation |
| 07/25/2002 | CA2434939A1 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | CA2434743A1 Stabilized brivudine topical formulations containing metal oxide pigments |
| 07/25/2002 | CA2434736A1 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
| 07/25/2002 | CA2434696A1 P27 prevents cellular migration |
| 07/25/2002 | CA2434636A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 07/25/2002 | CA2434544A1 Method for alleviating syndromes and conditions of discomfort of the mammalian intestinal and genito-urinary tracts |
| 07/25/2002 | CA2434483A1 Processes for enhanced production of pantothenate |
| 07/25/2002 | CA2434350A1 Novel receptors for $i(helicobacter pylori) and use thereof |
| 07/25/2002 | CA2434338A1 Pharmaceutical composition having reduced tendency for drug crystallization |
| 07/25/2002 | CA2434300A1 Synthesis of temozolomide and analogs |
| 07/25/2002 | CA2434296A1 Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase |
| 07/25/2002 | CA2434270A1 Use of mesna compounds to prevent adverse reactions to anti-neoplastic compositions |
| 07/25/2002 | CA2434068A1 Inhibitors of cruzipain and other cysteine proteases |
| 07/25/2002 | CA2433879A1 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/25/2002 | CA2433835A1 Tetrahydropyran derivatives as neurokinin receptor antagonists |
| 07/25/2002 | CA2433803A1 Biocatalytic and biomimetic generation of nitric oxide in situ at substrate/blood interfaces |
| 07/25/2002 | CA2432870A1 Substituted triazole diamine derivatives as kinase inhibitors |
| 07/25/2002 | CA2432776A1 Isoindolyl and isoquinolinyl aroyl pyrrole compounds |
| 07/25/2002 | CA2431919A1 Ccr5 antagonist and dp-178 polypeptide for treating viral infections |
| 07/25/2002 | CA2431506A1 Benz(g) indoles and their use as spla2 inhibitors |
| 07/25/2002 | CA2430577A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/25/2002 | CA2427058A1 Substituted felbamate derived compounds |
| 07/25/2002 | CA2426799A1 Method for producing purified hematinic iron-saccharidic complex and product produced |
| 07/25/2002 | CA2426775A1 Thienopyrimidine-based inhibitors of the src family |
| 07/25/2002 | CA2425135A1 Synthesis and antimicrobial activity of novel dicationic "reversed amidines" |
| 07/25/2002 | CA2425125A1 Method of treating parkinson's disease |
| 07/25/2002 | CA2369212A1 Combination therapy |
| 07/24/2002 | EP1225222A1 Novel tumor suppressor gene |
| 07/24/2002 | EP1225183A2 Human G-protein coupled receptor |
| 07/24/2002 | EP1225173A1 Naphthyridine derivatives |
| 07/24/2002 | EP1225170A2 Cycloheptene compounds, process for their preparation and pharmaceutical compositions containing them |
| 07/24/2002 | EP1225169A1 Radiation-activated cytotoxin therapy |
| 07/24/2002 | EP1225168A2 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| 07/24/2002 | EP1224945A1 Tension-relieving agents for ciliary muscle |
| 07/24/2002 | EP1224944A1 Skin immune function controlling agents |
| 07/24/2002 | EP1224938A1 Gugulipid for treating cognitive disorders, hyperglycaemia and skin disorders |
| 07/24/2002 | EP1224937A1 Stable preparations for treating bedsore, skin ulcer and wound |
| 07/24/2002 | EP1224936A1 Physical strength enhancing agents and glycogen accumulation promoting agents |
| 07/24/2002 | EP1224935A2 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| 07/24/2002 | EP1224934A2 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| 07/24/2002 | EP1224933A1 New combination of active ingredients containing alfuzosine and apomorphine |
| 07/24/2002 | EP1224931A1 Use of alkanoyloxymethyl esters for inhibiting histone deacetylase |
| 07/24/2002 | EP1224930A1 Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression |
| 07/24/2002 | EP1224928A1 Improved low residue cosmetic composition |
| 07/24/2002 | EP1224314A2 Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna |
| 07/24/2002 | EP1224291A1 Multiple sclerosis-related superantigen |
| 07/24/2002 | EP1224288A2 Processed human chemokines phc-1 and phc-2 |
| 07/24/2002 | EP1224285A2 27 human secreted proteins |
| 07/24/2002 | EP1224282A2 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 07/24/2002 | EP1224280A2 Design of high affinity rnase h recruiting oligonucleotide |
| 07/24/2002 | EP1224279A2 Microbe, microbial exopolysaccharide, and uses thereof |
| 07/24/2002 | EP1224220A2 Epo primary response gene 1, eprg1 |
| 07/24/2002 | EP1224207A1 5-hydroxysapogenin derivatives with anti-dementia activity |
| 07/24/2002 | EP1224206A1 Sapogenin derivatives and their use in the treatment of cognitive dysfunction |
| 07/24/2002 | EP1224205A1 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 07/24/2002 | EP1224204A1 Non-aromatic estrogenic steroids with a hydrocarbon substituent in position 11 |
| 07/24/2002 | EP1224203A2 Antisense modulation of protein kinase c-theta expression |
| 07/24/2002 | EP1224202A1 Antisense modulation of integrin-linked kinase expression |
| 07/24/2002 | EP1224201A1 32 human secreted proteins |
| 07/24/2002 | EP1224200A1 Tissue plasminogen activator-like protease |
| 07/24/2002 | EP1224197A1 Hygromycin derivatives |
| 07/24/2002 | EP1224195A1 C-aryl glucoside sglt2 inhibitors |
| 07/24/2002 | EP1224194A1 Hygromycin a prodrugs |
| 07/24/2002 | EP1224192A1 Half-sandwich ruthenium (ii) compounds comprising nitrogen containing ligands for treatment of cancer |
| 07/24/2002 | EP1224188A2 A salt of morphine |
| 07/24/2002 | EP1224187A2 Certain alkylene diamine-substituted heterocycles |
| 07/24/2002 | EP1224186A2 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation |
| 07/24/2002 | EP1224185A1 Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use |
| 07/24/2002 | EP1224184A1 Novel limonoids for use particularly in the treatment of cancer and method for producing the same |
| 07/24/2002 | EP1224183A2 Heterocyclic sodium/proton exchange inhibitors and method |
| 07/24/2002 | EP1224182A1 N-substituted 1-(lactone) isoquinolones for treating nervous disorders |
| 07/24/2002 | EP1224181A1 Substituted pyrroles as antiproliferative agents for the treatment of cancer |
| 07/24/2002 | EP1224180A2 Substituted azoles |
| 07/24/2002 | EP1224179A2 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 07/24/2002 | EP1224177A1 Process for preparing oxazolines from tetrahydrofurans |
| 07/24/2002 | EP1224175A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 07/24/2002 | EP1224174A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 07/24/2002 | EP1224173A1 Pyrazole derivatives as cannabinoid receptor antagonists |
| 07/24/2002 | EP1224172A1 Drugs for the treatment of malignant tumours |
| 07/24/2002 | EP1224171A1 Beta disubstituted metalloprotease inhibitors |